Generic Name:
romosozumab
Project Status:
Active
Therapeutic Area:
Osteoporosis, postmenopausal women
Manufacturer:
Amgen Canada Inc.
Brand Name:
Evenity
Project Line:
Reimbursement Review
Project Number:
SR0676-000
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
The treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture and who are at very high risk for future fracture.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.